Related Experiment Video
Updated: Aug 15, 2025

Use of Viral Entry Assays and Molecular Docking Analysis for the Identification of Antiviral Candidates against Coxsackievirus A16
Published on: July 15, 2019
Metabolic reprogramming as a novel therapeutic target for Coxsackievirus B3
Myeong Uk Kuk1, Yun Ji Ga1, Ye Jin Kim1
1Division of Life Sciences, College of Life Sciences and Bioengineering, Incheon National University, Incheon, Korea.
Insights
Coxsackievirus B3 infection alters host cell metabolism by increasing glycolysis. Inhibiting this metabolic pathway with glycolysis inhibitors effectively reduces viral load, offering a potential new treatment strategy for Coxsackievirus B3.
Area of Science:
- Virology
- Metabolic pathways
- Host-pathogen interactions
Background:
- Coxsackievirus B3 (CVB3) is an enterovirus causing severe human diseases like myocarditis and pancreatitis.
- Current therapeutic options for CVB3 infections are limited.
- Understanding CVB3's interaction with host cell metabolism is crucial for developing treatments.
Purpose of the Study:
- To investigate the metabolic alterations induced by CVB3 infection in host cells.
- To explore the potential of targeting host cell metabolism as an antiviral strategy against CVB3.
Main Methods:
- Measuring extracellular acidification rate (ECAR) to assess glycolysis levels.
- Utilizing gas chromatography-mass spectrometry (GC-MS) for metabolite analysis.
- Evaluating the efficacy of glycolysis inhibitors (2-Deoxy-D-glucose, sodium oxide) in reducing CVB3 titers.
Main Results:
- CVB3 infection significantly increases host cell glycolysis, indicated by elevated ECAR.
- Metabolomic analysis confirmed CVB3-induced metabolic reprogramming.
- Treatment with glycolysis inhibitors markedly reduced CVB3 viral titers post-infection.
Conclusions:
- CVB3 manipulates host cell metabolism, specifically enhancing glycolysis, to facilitate its replication.
- Inhibiting glycolysis presents a promising therapeutic strategy against CVB3 infections.
- Targeting host metabolic pathways offers a novel approach for controlling enterovirus replication.
Abstract:
Coxsackievirus B3 (CVB3) is a single-stranded RNA virus that belongs to the Enterovirus genus. CVB3 is a human pathogen associated with serious conditions such as myocarditis, dilated cardiomyopathy, and pancreatitis. However, there are no therapeutic interventions to treat CVB3 infections. In this study, we found that CVB3 induced metabolic alteration in host cells through increasing glycolysis level, as indicated by an increase in the extracellular acidification rate (ECAR). CVB3-mediated metabolic alteration was confirmed by metabolite change analysis using gas chromatography-mass spectrometry (GC-MS). Based on findings, a strategy to inhibit glycolysis has been proposed to treat CVB3 infection. Indeed, glycolysis inhibitors (2-Deoxy-D-glucose, sodium oxide) significantly reduced CVB3 titers after CVB3 infection, indicating that glycolysis inhibitors can be used as effective antiviral agents. Taken together, our results reveal a novel mechanism by which CVB3 infection is controlled by regulation of host cell metabolism.
Related Concept Videos
Myocarditis III: Medical Management
Retrovirus Life Cycles
Retroviruses
Mechanisms of Retrovirus-induced Cancers
Endocarditis III: Medical Management
Regulation of Metabolism

